WNT/β-catenin pathway activation in hepatocellular carcinoma: a clinical perspective

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127.
   PubMed Web of Science ®Google Scholar
• Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123–135.
   PubMed Web of Science ®Google Scholar
• Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323–331.
   PubMed Web of Science ®Google Scholar
• Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–1654.
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2(8256):1129–1133.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.
   PubMed Web of Science ®Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866–3884.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699.
   PubMed Web of Science ®Google Scholar
• Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33(5):1080–1086.
   PubMed Web of Science ®Google Scholar
• Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52(2):762–773.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–442.
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481.
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410–1426.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–3140.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10(1):34–42.
   PubMed Web of Science ®Google Scholar
• Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1(2):83–93.
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. WNT/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205.
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99–109.
   PubMed Web of Science ®Google Scholar
• Papkoff J, Brown AM, Varmus HE. The int-1 proto-oncogene products are glycoproteins that appear to enter the secretory pathway. Mol Cell Biol. 1987;7(11):3978–3984.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11–26.
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus H. Three decades of WNTs: a personal perspective on how a scientific field developed. EMBO J. 2012;31(12):2670–2684.
   PubMed Web of Science ®Google Scholar
• Bhanot P, Brink M, Samos CH, et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 1996;382(6588):225–230.
   PubMed Web of Science ®Google Scholar
• Wehrli M, Dougan ST, Caldwell K, et al. Arrow encodes an LDL-receptor-related protein essential for wingless signalling. Nature. 2000;407(6803):527–530.
   PubMed Web of Science ®Google Scholar
• Grumolato L, Liu G, Mong P, et al. Canonical and noncanonical WNTs use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 2010;24(22):2517–2530.
   PubMed Web of Science ®Google Scholar
• Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem. 1990;59:237–252.
   PubMed Web of Science ®Google Scholar
• He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–1512.
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422–426.
   PubMed Web of Science ®Google Scholar
• Yan D, Wiesmann M, Rohan M, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that WNT/beta -catenin signaling is activated in human colon tumors. Proc Natl Acad Sci U S A. 2001;98(26):14973–14978.
   Web of Science ®Google Scholar
• Li VS, Ng SS, Boersema PJ, et al. WNT signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012;149(6):1245–1256.
   PubMed Web of Science ®Google Scholar
• Moon RT, Campbell RM, Christian JL, McGrew LL, Shih J, Fraser S. XWNT-5A: a maternal WNT that affects morphogenetic movements after overexpression in embryos of Xenopus laevis. Development. 1993;119(1):97–111.
   Web of Science ®Google Scholar
• Slusarski DC, Yang-Snyder J, Busa WB, Moon RT. Modulation of embryonic intracellular Ca2+ signaling by WNT-5A. Dev Biol. 1997;182(1):114–120.
   Web of Science ®Google Scholar
• Oishi I, Suzuki H, Onishi N, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical WNT5a/JNK signalling pathway. Genes Cells. 2003;8(7):645–654.
   PubMed Web of Science ®Google Scholar
• Kühl M, Sheldahl LC, Park M, Miller JR, Moon RT. The WNT/Ca2+ pathway: a new vertebrate WNT signaling pathway takes shape. Trends Genet. 2000;16(7):279–283.
   PubMed Web of Science ®Google Scholar
• Van Camp JK, Beckers S, Zegers D, Van Hul W. WNT Signaling and the Control of Human Stem Cell Fate. Stem Cell Rev. Epub December 10, 2013.
   Google Scholar
• Lawrence PA, Struhl G, Casal J. Planar cell polarity: one or two pathways? Nat Rev Genet. 2007;8(7):555–563.
   Web of Science ®Google Scholar
• Klaus A, Birchmeier W. WNT signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–398.
   PubMed Web of Science ®Google Scholar
• Polakis P. WNT signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4(5).
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159–170.
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proc Natl Acad Sci U S A. 2000;97(7):3352–3357.
   Web of Science ®Google Scholar
• Ahmed Y, Hayashi S, Levine A, Wieschaus E. Regulation of armadillo by a Drosophila APC inhibits neuronal apoptosis during retinal development. Cell. 1998;93(7):1171–1182.
   Web of Science ®Google Scholar
• Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A. 2008;105(11):4283–4288.
   PubMed Web of Science ®Google Scholar
• Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24(3):245–250.
   PubMed Web of Science ®Google Scholar
• Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet. 2000;26(2):146–147.
   Web of Science ®Google Scholar
• Hidaka Y, Mitomi H, Saito T, et al. Alteration in the WNT/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–2448.
   Web of Science ®Google Scholar
• Chapman A, Durand J, Ouadi L, Bourdeau I. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors. J Clin Endocrinol Metab. 2011;96(9):E1477–E1481.
   Web of Science ®Google Scholar
• Yardy GW, Bicknell DC, Wilding JL, et al. Mutations in the AXIN1 gene in advanced prostate cancer. Eur Urol. 2009;56(3):486–494.
   PubMed Web of Science ®Google Scholar
• Polakis P. WNT signaling and cancer. Genes Dev. 2000;14(15):1837–1851.
   PubMed Web of Science ®Google Scholar
• Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997;275(5307):1784–1787.
   PubMed Web of Science ®Google Scholar
• Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275(5307):1787–1790.
   PubMed Web of Science ®Google Scholar
• Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275(5307):1790–1792.
   Web of Science ®Google Scholar
• de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998;95(15):8847–8851.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998;58(12):2524–2527.
   PubMed Web of Science ®Google Scholar
• Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T. Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 2001;61(18):6656–6659.
   PubMed Web of Science ®Google Scholar
• Garcia-Rostan G, Tallini G, Herrero A, D’Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59(8):1811–1815.
   Web of Science ®Google Scholar
• Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998;58(7):1344–1347.
   PubMed Web of Science ®Google Scholar
• Shitoh K, Konishi F, Iijima T, et al. A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol. 1999;52(9):695–696.
   Web of Science ®Google Scholar
• Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res. 1999;59(16):3880–3882.
   PubMed Web of Science ®Google Scholar
• Duval A, Gayet J, Zhou XP, Iacopetta B, Thomas G, Hamelin R. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res. 1999;59(17):4213–4215.
   Web of Science ®Google Scholar
• Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res. 2000;60(14):3872–3879.
   PubMed Web of Science ®Google Scholar
• Shiina H, Igawa M, Breault J, et al. The human T-cell factor-4 gene splicing isoforms, WNT signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res. 2003;9(6):2121–2132.
   Web of Science ®Google Scholar
• Howng SL, Huang FH, Hwang SL, et al. Differential expression and splicing isoform analysis of human Tcf-4 transcription factor in brain tumors. Int J Oncol. 2004;25(6):1685–1692.
   Web of Science ®Google Scholar
• Duval A, Iacopetta B, Ranzani GN, Lothe RA, Thomas G, Hamelin R. Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability. Oncogene. 1999;18(48):6806–6809.
   Web of Science ®Google Scholar
• Milovanovic T, Planutis K, Nguyen A, et al. Expression of WNT genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol. 2004;25(5):1337–1342.
   Web of Science ®Google Scholar
• Flahaut M, Meier R, Coulon A, et al. The WNT receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the WNT/beta-catenin pathway. Oncogene. 2009;28(23):2245–2256.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Schittenhelm J, Guo K, et al. Upregulation of frizzled 9 in astrocytomas. Neuropathol Appl Neurobiol. 2006;32(6):615–624.
   PubMed Web of Science ®Google Scholar
• Rhee CS, Sen M, Lu D, et al. WNT and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene. 2002;21(43):6598–6605.
   PubMed Web of Science ®Google Scholar
• Khan NI, Bradstock KF, Bendall LJ. Activation of WNT/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol. 2007;138(3):338–348.
   Web of Science ®Google Scholar
• Janssens N, Andries L, Janicot M, Perera T, Bakker A. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol. 2004;25(4):161–171.
   Google Scholar
• Thiele S, Rauner M, Goettsch C, et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem. 2011;112(6):1593–1600.
   Web of Science ®Google Scholar
• Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A. 1998;95(17):10164–10169.
   Web of Science ®Google Scholar
• Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 2004;127(4):1110–1122.
   Web of Science ®Google Scholar
• Terasaki H, Saitoh T, Shiokawa K, Katoh M. Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT – beta-catenin – TCF signaling pathway. Int J Mol Med. 2002;9(2):107–112.
   Web of Science ®Google Scholar
• Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24(41):6201–6212.
   Web of Science ®Google Scholar
• Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31(2):141–149.
   PubMed Web of Science ®Google Scholar
• Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol. 2008;43(5):378–389.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Wang J, Han X, Zhou J, Linder S. Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors. Int J Cancer. 1998;78(1):95–99.
   Web of Science ®Google Scholar
• Ko J, Ryu KS, Lee YH, et al. Human secreted frizzled-related protein is down-regulated and induces apoptosis in human cervical cancer. Exp Cell Res. 2002;280(2):280–287.
   Web of Science ®Google Scholar
• Ugolini F, Charafe-Jauffret E, Bardou VJ, et al. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene. 2001;20(41):5810–5817.
   PubMed Web of Science ®Google Scholar
• Ekström EJ, Sherwood V, Andersson T. Methylation and loss of secreted Frizzled-related protein 3 enhances melanoma cell migration and invasion. PLoS One. 2011;6(4):e18674.
   Web of Science ®Google Scholar
• Kawano Y, Kypta R. Secreted antagonists of the WNT signalling pathway. J Cell Sci. 2003;116(Pt 13):2627–2634.
   PubMed Web of Science ®Google Scholar
• Cowling VH, D’Cruz CM, Chodosh LA, Cole MD. c-Myc transforms human mammary epithelial cells through repression of the WNT inhibitors DKK1 and SFRP1. Mol Cell Biol. 2007;27(14):5135–5146.
   PubMed Web of Science ®Google Scholar
• Cho JH, Dimri M, Dimri GP. A positive feedback loop regulates the expression of polycomb group protein BMI1 via WNT signaling pathway. J Biol Chem. 2013;288(5):3406–3418.
   Web of Science ®Google Scholar
• Hsieh A, Kim HS, Lim SO, Yu DY, Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate WNT/β-catenin signaling. Cancer Lett. 2011;300(2):162–172.
   Web of Science ®Google Scholar
• Liu J, Ding X, Tang J, et al. Enhancement of canonical WNT/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One. 2011;6(11):e27496.
   Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Huang K, Zhang JX, Han L, et al. MicroRNA roles in beta-catenin pathway. Mol Cancer. 2010;9:252.
   Web of Science ®Google Scholar
• Saydam O, Shen Y, Würdinger T, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the WNT/beta-catenin signaling pathway. Mol Cell Biol. 2009;29(21):5923–5940.
   PubMed Web of Science ®Google Scholar
• Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009;114(2):404–414.
   Web of Science ®Google Scholar
• Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and WNT signaling. Cell Cycle. 2012;11(7):1273–1281.
   PubMed Web of Science ®Google Scholar
• Kim NH, Cha YH, Kang SE, et al. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle. 2013;12(10):1578–1587.
   PubMed Web of Science ®Google Scholar
• Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7(9):e44206.
   Web of Science ®Google Scholar
• Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating WNT signaling. Hepatology. 2012;56(5):1631–1640.
   PubMed Web of Science ®Google Scholar
• Takigawa Y, Brown AM. WNT signaling in liver cancer. Curr Drug Targets. 2008;9(11):1013–1024.
   PubMed Web of Science ®Google Scholar
• Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155(6):1795–1801.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157(3):763–770.
   Web of Science ®Google Scholar
• Wong CM, Fan ST, Ng IO. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92(1):136–145.
   PubMed Web of Science ®Google Scholar
• Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155(3):703–710.
   PubMed Web of Science ®Google Scholar
• Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8(2):450–456.
   Web of Science ®Google Scholar
• Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26(5):774–780.
   PubMed Web of Science ®Google Scholar
• Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009;49(3):821–831.
   PubMed Web of Science ®Google Scholar
• Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between beta-catenin mutations and expression of WNT-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008;7:21.
   PubMed Web of Science ®Google Scholar
• Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013;102(2):74–83.
   PubMed Web of Science ®Google Scholar
• Amit S, Hatzubai A, Birman Y, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the WNT pathway. Genes Dev. 2002;16(9):1066–1076.
   PubMed Web of Science ®Google Scholar
• Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10(12):1443–1454.
   PubMed Web of Science ®Google Scholar
• Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005;25(1):70–76.
   Web of Science ®Google Scholar
• Murata M, Miyoshi Y, Ohsawa M, et al. Accumulation of beta-catenin in the cytoplasm and the nuclei during the early hepatic tumorigenesis. Hepatol Res. 2001;21(2):126–135.
   Web of Science ®Google Scholar
• Jung HY, Jun S, Lee M, et al. PAF and EZH2 induce WNT/β-catenin signaling hyperactivation. Mol Cell. 2013;52(2):193–205.
   PubMed Web of Science ®Google Scholar
• Lee E, Salic A, Krüger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the WNT pathway. PLoS Biol. 2003;1(1):E10.
   Web of Science ®Google Scholar
• Feng GJ, Cotta W, Wei XQ, et al. Conditional disruption of Axin1 leads to development of liver tumors in mice. Gastroenterology. 2012;143(6):1650–1659.
   Web of Science ®Google Scholar
• Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21(31):4863–4871.
   PubMed Web of Science ®Google Scholar
• Bala S, Sulekova Z, Ballhausen WG. Constitutive APC exon 14 skipping in early-onset familial adenomatous polyposis reveals a dramatic quantitative distortion of APC gene-specific isoforms. Hum Mutat. 1997;10(3):201–206.
   Web of Science ®Google Scholar
• Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L, Weitman SD. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol. 1998;20(3):274–278.
   Web of Science ®Google Scholar
• Su LK, Abdalla EK, Law CH, Kohlmann W, Rashid A, Vauthey JN. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer. 2001;92(2):332–339.
   Web of Science ®Google Scholar
• Katoh H, Shibata T, Kokubu A, et al. Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes Chromosomes Cancer. 2006;45(11):1050–1057.
   Web of Science ®Google Scholar
• Csepregi A, Röcken C, Hoffmann J, et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134(5):579–589.
   PubMed Web of Science ®Google Scholar
• Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One. 2010; 5(3):e9749.
   PubMed Web of Science ®Google Scholar
• Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013;8(2):e55761.
   PubMed Web of Science ®Google Scholar
• Jain S, Chang TT, Hamilton JP, et al. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS One. 2011;6(11):e26799.
   Web of Science ®Google Scholar
• Lee HH, Uen YH, Tian YF, et al. WNT-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1562–1569.
   PubMed Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So SK. Blockade of WNT-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009;8:76.
   PubMed Web of Science ®Google Scholar
• Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of WNT-1 expression. Hepatology. 2005;41(5):1096–1105.
   Web of Science ®Google Scholar
• Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between WNT3 and frizzled-7 leads to activation of the WNT/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008;48(5):780–791.
   Web of Science ®Google Scholar
• Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ, Liu XH. Loss of WNT5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol. 2012;18(12):1328–1338.
   Web of Science ®Google Scholar
• Yuzugullu H, Benhaj K, Ozturk N, et al. Canonical WNT signaling is antagonized by noncanonical WNT5a in hepatocellular carcinoma cells. Mol Cancer. 2009;8:90.
   PubMed Web of Science ®Google Scholar
• Toyama T, Lee HC, Koga H, Wands JR, Kim M. Noncanonical WNT11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res. 2010;8(2):254–265.
   Web of Science ®Google Scholar
• Yu B, Yang X, Xu Y, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50(5):948–957.
   Web of Science ®Google Scholar
• Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–826.
   PubMed Web of Science ®Google Scholar
• Ding Z, Qian YB, Zhu LX, Xiong QR. Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. World J Gastroenterol. 2009;15(21):2595–2601.
   Web of Science ®Google Scholar
• Deng Y, Yu B, Cheng Q, et al. Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J Cancer Res Clin Oncol. 2010;136(8):1161–1167.
   Web of Science ®Google Scholar
• Fatima S, Lee NP, Tsang FH, et al. Dickkopf 4 (DKK4) acts on WNT/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma. Oncogene. 2012;31(38):4233–4244.
   Web of Science ®Google Scholar
• Quan H, Zhou F, Nie D, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2013, Epub ahead of print.
   Google Scholar
• Bengochea A, de Souza MM, Lefrançois L, et al. Common dysregulation of WNT/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008;99(1):143–150.
   Web of Science ®Google Scholar
• Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M. Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis. 2012;1:e31.
   Web of Science ®Google Scholar
• Tung EK, Wong BY, Yau TO, Ng IO. Upregulation of the WNT co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One. 2012;7(5):e36565.
   PubMed Web of Science ®Google Scholar
• Garber K. Drugging the WNT pathway: problems and progress. J Natl Cancer Inst. 2009;101(8):548–550.
   Google Scholar
• Voronkov A, Krauss S. WNT/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des. 2013;19(4):634–664.
   Web of Science ®Google Scholar
• Development pipeline [webpage on the Internet]. Redwood City, CA:OncoMed Pharmaceuticals. Availalbe from: http://www.oncomed.com/Pipeline.html. Accessed November 21, 2013.
   Google Scholar
• Gurney A, Axelrod F, Bond CJ, et al. WNT pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA. 2012;109(29):11717–11722.
   PubMed Web of Science ®Google Scholar
• Polakis P. Drugging WNT signalling in cancer. EMBO J. 2012;31(12):2737–2746.
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–3536.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting WNT/β-catenin pathway. Liver Int. 2012;32(5):752–760.
   PubMed Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So SK. Soluble Frizzled-7 receptor inhibits WNT signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer. 2011;10:16.
   PubMed Web of Science ®Google Scholar
• Nambotin SB, Lefrancois L, Sainsily X, et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol. 2011;54(2):288–299.
   Web of Science ®Google Scholar
• Fujimoto T, Tomizawa M, Yokosuka O. SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol. 2009;35(4):861–866.
   Web of Science ®Google Scholar
• Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer. 2010;126(10):2426–2436.
   Web of Science ®Google Scholar
• Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 2007;9(11):951–959.
   PubMed Web of Science ®Google Scholar
• Wang XH, Sun X, Meng XW, et al. beta-catenin siRNA regulation of apoptosis- and angiogenesis-related gene expression in hepatocellular carcinoma cells: potential uses for gene therapy. Oncol Rep. 2010;24(4):1093–1099.
   Web of Science ®Google Scholar
• Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012;11(12):923–936.
   PubMed Web of Science ®Google Scholar
• Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes WNT signalling. Nature. 2009;461(7264):614–620.
   PubMed Web of Science ®Google Scholar
• Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One. 2012;7(11):e48670.
   PubMed Web of Science ®Google Scholar
• Waaler J, Machon O, Tumova L, et al. A novel tankyrase inhibitor decreases canonical WNT signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72(11):2822–2832.
   PubMed Web of Science ®Google Scholar
• Lau T, Chan E, Callow M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73(10):3132–3144.
   PubMed Web of Science ®Google Scholar
• Busch AM, Johnson KC, Stan RV, et al. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211.
   PubMed Web of Science ®Google Scholar
• Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of WNT-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 2009;5(2):100–107.
   PubMed Web of Science ®Google Scholar
• Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507.
   PubMed Web of Science ®Google Scholar
• LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res. 2010;16(12):3121–3129.
   PubMed Web of Science ®Google Scholar
• Yang W, Yan HX, Chen L, et al. WNT/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68(11):4287–4295.
   PubMed Web of Science ®Google Scholar
• Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280–281.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by WNT-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67(22):10831–10839.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–1024.
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820–824.
   PubMed Web of Science ®Google Scholar
• Tsai ST, Tsou CC, Mao WY, et al. Label-free quantitative proteomics of CD133-positive liver cancer stem cells. Proteome Sci. 2012;10(1):69.
   Google Scholar
• Noda T, Nagano H, Takemasa I, et al. Activation of WNT/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 2009;100(10):1647–1658.
   PubMed Web of Science ®Google Scholar
• Xu N, Shen C, Luo Y, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and WNT signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun. 2012;425(2):468–472.
   PubMed Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Savic R, et al. WNT-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18(18):4997–5007.
   PubMed Web of Science ®Google Scholar